Loading
Old version — revision 2
This is a fixed snapshot of Cellular senescence, saved by Import. It is not edited and it is not updated; the article may have changed since.
Edit summary: Re-import of content/cellular-senescence.md — the file changed after the initial import. Not an edit.
Read the current versionWhat this revision changedAll 2 revisions
A stable arrest of cell division, triggered by telomere attrition or stress, in which the arrested cell stays metabolically active and secretes inflammatory factors.
Cellular senescence is a stable exit from the cell cycle in which a cell stops dividing but does not die: it remains metabolically active, resists apoptosis and changes what it secretes. It is one of the Hallmarks of aging and one of the clearest cases of antagonistic pleiotropy in mammalian biology. The same arrest that prevents damaged cells from becoming tumours degrades the surrounding tissue when senescent cells accumulate with age.
Leonard Hayflick and Paul Moorhead reported in 1961 that normal human diploid fibroblasts divide a limited number of times in culture and then stop, contradicting the then-standard belief that vertebrate cells were immortal under good conditions.1 The limit is now attributed largely to progressive telomere shortening, but replicative exhaustion turned out to be only one route into the state.
Senescence has no single definitive marker, a persistent methodological problem. Investigators typically require several features together: absence of proliferation markers, expression of the cyclin-dependent kinase inhibitors p16INK4a or p21CIP1, senescence-associated β-galactosidase activity detected at pH 6, loss of nuclear Lamin B1, and evidence of a persistent DNA damage response.2 Each of these also appears in cells that are not senescent. p16 expression in particular can be induced in macrophages as a reversible physiological response, which confounds any attempt to quantify senescent burden in tissue by p16 alone.3
Terminology"Senescence" in this article means the cellular state. It is mechanistically unrelated to organismal senescence, the whole-body decline the word denotes in demography and evolutionary biology, although popular coverage often conflates the two.
Replicative senescence follows telomere attrition and the DNA damage response it provokes at uncapped chromosome ends. Oncogene-induced senescence is triggered by aberrant proliferative signalling. In 1997 Serrano and colleagues showed that expressing oncogenic RAS in normal human cells drives them into arrest instead of transformation, establishing senescence as a barrier against tumours.4 Stress-induced premature senescence follows oxidative damage, mitochondrial impairment, irradiation or proteotoxic stress without any telomere involvement. Therapy-induced senescence is a common outcome of cytotoxic chemotherapy and contributes to the long-term functional deficits seen in cancer survivors.
Senescence also has programmed roles outside pathology. In 2013 two independent groups reported that transient senescent populations appear at defined sites during mammalian embryonic development, including the apical ectodermal ridge, where they shape tissue patterning before macrophages clear them.5 Senescence is therefore a mechanism with normal uses, not something evolution overlooked; the harm comes from its persistence in aged tissue.
Senescent cells matter beyond their own arrest because of the senescence-associated secretory phenotype, or SASP. This program of secreted interleukins, chemokines, growth factors and matrix-remodelling proteases was characterized by Coppé, Campisi and colleagues in 2008 at the Buck Institute and Lawrence Berkeley National Laboratory.6 SASP composition varies with the trigger and the cell type, and there is no canonical SASP. Cytosolic DNA sensing through the cGAS-STING pathway is one of its principal upstream activators, which links the secretory program to genome instability and to leaked mitochondrial DNA.
The SASP reinforces arrest in the secreting cell, recruits immune cells to clear it, and induces senescence in neighbouring cells. Through this paracrine spread a small number of senescent cells can alter a large volume of tissue. The chronic form of the SASP is one of the main proposed sources of sterile chronic inflammation in old animals, and it impairs the function of nearby progenitors, which connects senescence to stem cell exhaustion. Transplanting a modest number of senescent cells into young mice is enough to produce measurable physical dysfunction that spreads beyond the injection site.7
Senescent cells are more than debris. Beyond tumour suppression and development, they take part in wound healing. In mice, senescent fibroblasts and endothelial cells that appear at wound sites secrete PDGF-AA and accelerate closure, and animals unable to mount that response heal more slowly.8 Senescence of activated hepatic stellate cells limits liver fibrosis in mouse models. Indiscriminate clearance is therefore not obviously good. Studies using genetic ablation of p16-high cells have reported that removing certain populations, including liver sinusoidal endothelial cells, causes tissue damage instead of rejuvenation.9
For four decades senescence was treated as an artifact of culture whose relevance in vivo was uncertain. Two developments changed that. Reliable in vivo markers and reporter mice made senescent cells visible in tissue, and transgenic systems allowed them to be killed selectively.
The transgenic results, first in a progeroid strain and then in normally aged animals, established that senescent cells are causally involved in mouse aging phenotypes and not merely present.10 That finding prompted the search for drugs with the same effect, which became the field of Senolytics. Progress since has been slower than the mouse work implied. Early human studies have been small and open-label, focused on surrogate measures such as senescent-cell burden in fat biopsies. A phase 2 trial of a locally injected senolytic for osteoarthritis run by Unity Biotechnology did not beat placebo, and a randomized trial of intermittent dasatinib plus quercetin in postmenopausal women missed its primary bone-turnover endpoint.11 The alternative approach uses senomorphics, which suppress the SASP without killing the cell; Rapamycin and JAK inhibitors both blunt SASP output in animal models.
The disagreementIt is unsettled whether senescent cells are a primary driver of aging or one downstream consequence among many. Clearance experiments show that they cause specific phenotypes in mice. They do not show that senescence sits upstream of the other hallmarks, and the mouse strains used are not a straightforward model of human aging.
No validated assay can currently quantify senescent burden in living humans. That blocks the obvious trial design: measure burden, remove cells, measure again, follow outcomes. The NIH's Cellular Senescence Network was created partly to build a tissue atlas that would support such measures, and its central task remains defining senescence specifically enough for biomarker use.
The deeper issue is heterogeneity. Senescent cells derived from different tissues by different triggers share the arrest but differ in secretome, in the anti-apoptotic pathways they depend on, and probably in whether they help or harm. A senolytic that kills one subtype may leave another untouched, a plausible explanation for the gap between mouse results and human trial outcomes. Whether the state is truly irreversible is also in question. Transient reprogramming can restore proliferative capacity to senescent cells in culture, which suggests that the arrest is enforced epigenetically and not written into the genome.
The clinical question that follows is which diseases to target. Senescent-cell involvement has been argued for idiopathic pulmonary fibrosis, osteoarthritis, diabetic kidney disease, atherosclerosis and Alzheimer's disease, and small early-phase studies exist in several of these. The geroscience version of the argument goes further: clearing senescent cells would delay several such conditions at once and so demonstrate a change in the aging process, not in one disease. Testing that claim requires an outcome measure the field does not yet have. Until one exists, senescence therapeutics are assessed one indication at a time on ordinary clinical endpoints rather than on Biological age or Healthspan.
paperHayflick, L., Moorhead, P. S. "The serial cultivation of human diploid cell strains." Experimental Cell Research, 1961.↩Human cells in culture; the doubling limit is a property of cells in a dish and was never measured in a living person.
paperDimri, G. P. et al. "A biomarker that identifies senescent human cells in culture and in aging skin in vivo." PNAS, 1995. ↩
paperHall, B. M. et al. "p16(Ink4a) and senescence-associated β-galactosidase can be induced in macrophages as part of a reversible response to physiological stimuli." Aging, 2017.↩Mouse macrophages responding to ordinary stimuli, which is why p16 staining alone cannot be read as a count of senescent cells.
paperSerrano, M., Lin, A. W., McCurrach, M. E., Beach, D., Lowe, S. W. "Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a." Cell, 1997. ↩
paperMuñoz-Espín, D. et al. "Programmed cell senescence during mammalian embryonic development." Cell, 2013. ↩
paperCoppé, J.-P. et al. "Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor." PLoS Biology, 2008. ↩
paperXu, M. et al. "Senolytics improve physical function and increase lifespan in old age." Nature Medicine, 2018. ↩
paperDemaria, M. et al. "An essential role for senescent cells in optimal wound healing through secretion of PDGF-AA." Developmental Cell, 2014. ↩
paperGrosse, L. et al. "Defined p16High senescent cell types are indispensable for mouse healthspan." Cell Metabolism, 2020. ↩
paperBaker, D. J. et al. "Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders." Nature, 2011; and Baker, D. J. et al. "Naturally occurring p16Ink4a-positive cells shorten healthy lifespan." Nature, 2016.↩Both use an engineered transgene to kill p16-positive cells in mice, not a drug; the 2011 strain is progeroid and the 2016 one normally aged.
paperFarr, J.N. et al. "Effects of intermittent senolytic therapy on bone metabolism in postmenopausal women: a randomized controlled trial." Nature Medicine, 2024.↩The trial reported signals in prespecified subgroups, which is hypothesis-generating rather than a demonstration of benefit.